WHAT WINDMIL Therapeutics® DOES
When it comes to cell therapy – cell source matters. At WindMIL, we are harnessing the power of bone marrow derived lymphocytes (MILs) to develop ground-breaking immunotherapies to treat cancer patients. The bone marrow is a natural reservoir of T cells with unique advantages including inherent tumor-specificity. We have perfected an efficient and rapid process to extract, activate and expand MILs for future commercial applications. Our lead program is in a large Phase 2b study in high-risk multiple myeloma with additional programs in solid tumors using MILs advancing to the clinic. We are also advancing programs to supercharge MILs through genetic-modification.
WHAT MAKES MILS SPECIAL
MILsTM represent a novel class of cell therapy. Owing to their derivation from the bone marrow, a natural reservoir for memory T cells, MILs are marked by inherent tumor specificity, low toxicity, and long-term persistence. The ability to harness this long-term memory component is what differentiates MIL-therapy from other cell-therapy approaches, which rely predominantly on T cells found in the periphery.
THE EXPERTS THAT DRIVE WINDMIL
Reach out to Windmil